ORALLY ACTIVE MANNOSIDES SUBVERT ANTIBIOTIC RESISTANCE IF E COLI IN BLADDER

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 抗药性病原体的扩散已被描述为迫在眉睫的健康危机1。这在尿路感染(UTI)中日益明显，尿路病原体对甲氧普林-磺胺甲恶唑(TMP-SMZ)一线经验疗法的耐药性使治疗复杂化，并促使替代抗菌剂的使用2。因此，耐多药的尿路病原体正在增加，使尿路感染的直接治疗变得越来越困难。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Proliferation of antibiotic-resistant pathogens has been described as an impending health crisis1. This is increasingly evident for urinary tract infections (UTI) where resistance to first-line empiric therapy with trimethoprim-sulfamethoxazole (TMP-SMZ) by uropathogens complicates treatment, and drives use of alternate antimicrobial agents2. As a consequence, multidrug-resistant uropathogens are on the rise, making the straightforward treatment of UTI increasingly difficult.